CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(35 sites)

France

CHU Amiens Picardie site Sud, Amiens

CHU d'Angers, Angers

CH Avignon, Avignon

CHRU Jean Minjoz, Besançon

Centre Hospitalier de Béziers, Béziers